Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-dose Study for the Evaluation of the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of KP-001

NCT06619054 is registered in ClinicalTrials.gov with Kaken Pharmaceutical as lead sponsor.

NCT NCT06619054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06619054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-dose Study for the Evaluation of the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of KP-001
Lead sponsor
Kaken Pharmaceutical
Phase
Phase 1
Overall status
Completed
Start date
October 24, 2024
Completion date
July 31, 2025
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adults, hepatic impairment